Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspire-Lakewood HoldingsASBP +2.42%11 EV-to-EBITDA is -4.85 as of Sep. 11, 2026. GuruFocus rates ASBP with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 401 Biotechnology companies, Aspire-Lakewood Holdings ranks worse than 249376.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aspire-Lakewood Holdings's enterprise value is $8.43 Mil.
Aspire-Lakewood Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.74 Mil. Therefore, Aspire-Lakewood Holdings's EV-to-EBITDA for today is -4.85.
The historical rank and industry rank for Aspire-Lakewood Holdings's EV-to-EBITDA or its related term are showing as below:
ASBP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.85 Med: -0.44 Max: 3.41
Current: -4.85
During the past 4 years, the highest EV-to-EBITDA of Aspire-Lakewood Holdings was 3.41. The lowest was -4.85. And the median was -0.44.
ASBP's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.35
vs ASBP: -4.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aspire-Lakewood Holdings's PE Ratio (TTM) for today is calculated as:
Aspire-Lakewood Holdings's share price for today is $9.25.
Aspire-Lakewood Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-109.761.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aspire-Lakewood Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspire-Lakewood Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aspire-Lakewood Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aspire-Lakewood Holdings's EV-to-EBITDA falls into.
Aspire-Lakewood Holdings's current Enterprise Value is $8.43 Mil.
Aspire-Lakewood Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspire-Lakewood Holdings (ASBP) has a EV-to-EBITDA of -4.85 as of Sep. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aspire-Lakewood Holdings. According to the industry distribution chart, Aspire-Lakewood Holdings ranks #999999 out of 401 companies in the Biotechnology industry.
Is Aspire-Lakewood Holdings' EV-to-EBITDA too high?
Aspire-Lakewood Holdings' current EV-to-EBITDA is -4.85. Based on the distribution chart, Aspire-Lakewood Holdings ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aspire-Lakewood Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Aspire-Lakewood Holdings' EV-to-EBITDA compare to PDSB and KPRX?
According to the Biotechnology industry distribution chart, Aspire-Lakewood Holdings ranks #999999 out of 401 companies for EV-to-EBITDA. This places Aspire-Lakewood Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 13.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.35, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aspire-Lakewood Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspire-Lakewood Holdings's current EV-to-EBITDA is -4.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspire-Lakewood Holdings stock overvalued right now?
Aspire-Lakewood Holdings (ASBP) has a current EV-to-EBITDA of -4.85. The current EV-to-EBITDA is -4.85. Aspire-Lakewood Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aspire-Lakewood Holdings (ASBP), the current EV-to-EBITDA is -4.85 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
11GF Score
Get the complete analysis for ASBP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASBP has been successfully added to your 
